The IPO is now effective; pricing and first day of trading are expected within 1-2 trading days. Traders should monitor for the final pricing announcement and initial trading performance, which will reflect investor demand for this ATTOBODY platform biotech.
Price Chart
Executive Summary
Attovia Therapeutics' S-1 registration for its IPO became effective on August 4, 2026, allowing the company to proceed with an offering of 17,000,000 shares at an estimated $17.00 per share, targeting approximately $265 million in net proceeds. The clinical-stage biopharma plans to use proceeds to fund Phase 2 trials for its ATTOBODY-based candidates and extend cash runway into 2029. This milestone clears the path for the company's public listing and first day of trading.
Key Facts
- EFFECT notice for Registration Statement S-1 (File No. 333-297452) declared effective August 4, 2026.
- IPO of 17,000,000 shares at estimated $17.00 per share, targeting ~$265 million net proceeds (from prior S-1/A).
- Proceeds to fund Phase 2 trials for lead candidate ATTO-1310 and ATTO-2306, plus early development of ATTO-1091.
- Cash runway extended into 2029.
- Cross-filing S-1/A filed August 4, 2026 provides full offering details.
Financial Impact
Estimated net proceeds of ~$265 million from 17M-share IPO at $17.00 per share
Risk Factors
- Market conditions may cause final pricing to deviate from the $17.00 estimate.
- Clinical-stage biotech: pipeline candidates have yet to achieve Phase 3 or regulatory approval.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002535 |
| Document: 9999999995-26-002535-index.html | 9999999995-26-002535 |
| Document: 9999999995-26-002535.txt | 9999999995-26-002535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 3/A | $16.21 | awaiting T+20 | — | $15.00 (−7.46%) |
Oct 8, 2026 19d ago | 3/A | $16.21 | awaiting T+20 | — | $15.00 (−7.46%) |
Sep 28, 2026 29d ago | Press Release | $18.16 $15.00 | ▼ −17.40% | ▼ −18.12% | $15.00 (−17.40%) |
Sep 2, 2026 7w ago | Press Release | $24.20 $17.14 | ▼ −29.17% | ▼ −28.06% | $15.00 (−38.02%) |
Aug 28, 2026 8w ago | 144 / CLUSTER | $21.40 $18.16 | ▼ −15.14% | ▼ −14.95% | $15.00 (−29.91%) |
Aug 13, 2026 10w ago | Insider Buy | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $15.00 (−24.47%) |
Aug 13, 2026 10w ago | Insider Cluster | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $15.00 (−24.47%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.65 $22.86 | ▲ +22.57% | ▲ +23.63% | $15.00 (−19.57%) |
Aug 7, 2026 11w ago | Insider Cluster | $19.84 $23.66 | ▲ +19.25% | ▲ +20.17% | $15.00 (−24.40%) |
Aug 7, 2026 11w ago | Insider Cluster | $20.17 $25.55 | ▲ +26.67% | ▲ +27.07% | $15.00 (−25.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers